SHR A1912
Alternative Names: SHR-A1912Latest Information Update: 02 Jul 2024
At a glance
- Originator Shanghai Hengrui Pharmaceutical
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Non-Hodgkin's lymphoma
- Phase I B-cell lymphoma
Most Recent Events
- 02 Jul 2024 Phase-I clinical trials in Non-Hodgkin's lymphoma in USA (Parenteral), prior to July 2024 (Shanghai Hengrui Pharmaceutical pipeline, July 2024)
- 31 May 2024 Efficacy, pharmacokinetics and adverse events data from a phase I trial in B cell lymphoma presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 17 Nov 2023 Phase-I/II clinical trials in B-cell lymphoma (Combination therapy, First-line therapy) in China (Parenteral) (NCT06104553)